

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Dapagliflozin for treating heart failure with reduced ejection fraction

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

| |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
| No |

| |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
| n/a |

| |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
| n/a |

| |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
| No |

Approved by Associate Director (name): Nicole Elliott

Date: 11/03/2020

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of Dapagliflozin for treating heart failure with reduced ejection fraction

Issue date: March 2020